| Literature DB >> 35211515 |
Arlana G Taylor1,2, Andrew I Ignaszewski2, Shannon S D Bredin3,4, John S Hill5, Erin M Shellington3,4, Darren E R Warburton1,3,6.
Abstract
BACKGROUND: Inflammatory activation has been associated with the severity and progression of chronic heart failure (CHF). Although cardiac rehabilitation is an important therapy, acute bouts of exercise may lead to increases in pro-inflammatory cytokines with exercise intensity mediating these changes.Entities:
Keywords: cardiac rehabilitation; cytokines; exercise; heart failure; inflammatory markers; interval training; training
Year: 2022 PMID: 35211515 PMCID: PMC8860824 DOI: 10.3389/fcvm.2021.752531
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Study flow diagram.
Participant characteristics (values are means ± SD).
|
|
|
|
|---|---|---|
| Age (y) | 60.1 ± 6.7 | 57.9 ± 9.8 |
| Height (cm) | 177.7 ± 5.3 | 177.7 ± 5.4 |
| Weight (kg) | 96.3 ± 23.4 | 96.0 ± 13.5 |
| BMI (kg.m2) | 30.2 ± 5.34 | 30.5 ± 4.6 |
| Ejection Fraction | 0.24 ± 0.07 | 0.30 ± 0.11 |
| VO2peak (mL.kg−1.min−1) | 14.9 ± 5.3 | 12.5 ± 3.9 |
|
| ||
| Type 1 DM | 1 | 2 |
| Type 2 DM | 1 | 1 |
|
| ||
| Class 1 | 2 | 0 |
| Class 2 | 4 | 5 |
| Class 3a | 1 | 2 |
|
| ||
| Ischemic | 3 | 4 |
| Valvular | 1 | 0 |
| Dilated | 1 | 0 |
| Idiopathic | 0 | 3 |
|
| ||
| NSR | 3 | 6 |
| Atrial fibrillation/flutter | 1 | 0 |
| Paced | 3 | 1 |
| Ventricular pacemaker | 2 | 2 |
| AICD | 3 | 4 |
|
| ||
| <1 yr | 0 | 1 |
| 1–5 yr | 5 | 3 |
| 6–10 yr | 1 | 2 |
| 11–20 yr | 1 | 1 |
|
| ||
| 500–1,000 | 4 | 2 |
| 1,001–2,000 | 1 | 1 |
| 2,001–3,000 | 1 | 1 |
| 3,001–4,000 | 1 | 1 |
| 4,001–5,000 | 0 | 1 |
| 5,001–10,000 | 0 | 1 |
| >10,000 | 1 | 0 |
|
| ||
| Low | 1 | 2 |
| Normal | 6 | 5 |
|
| ||
| ASA | 4 | 4 |
| Beta blocker (CoReg, atenolol, monocor, bisoprolol) | 7 | 6 |
| ARB (atacand) | 5 | 4 |
| Digoxin | 4 | 4 |
| Diuretic (lasix) | 6 | 7 |
| Amiodarone (antiarrhythmic) | 1 | 2 |
| Cholesterol-lowering (lipitor, crestor, simvastatin) | 2 | 3 |
| Anti-coagulant (coumadin) | 5 | 4 |
| Plavix | 0 | 1 |
| ACE inhibitor (altace, captopril, accupril) | 3 | 2 |
| Calcium channel blocker (norvasc) | 2 | 1 |
| Vasodilators (nitroglycerine: patch, spray, tablets; hydralazine) | 2 | 1 |
| Hyperglycemic agents (Metformin, Glyburide, Insulin) | 2 | 3 |
| Other (testosterone, eltroxin, synthroid, pantolec, allopurinol, effexor, welbutrin, celexa, cholchicine, valium, halcion) | 5 | 3 |
No significant differences between participants at baseline (p < 0.05).
ARB, angiotensin II receptor blocker; ACE, angiotensin-converting-enzyme inhibitor.
Cardiorespiratory responses at rest and during incremental to maximal exercise testing (values are means ± SD).
|
|
|
|
|---|---|---|
|
| ||
| Heart rate (bpm) | 88.6 ± 21.8 | 72.7 ± 23.5 |
| Oxyhemoglobin saturation (%) | 97.6 ± 1.4 | 98.3 ± 1.0 |
| Systolic blood pressure (mmHg) | 101.3 ± 16.4 | 105.0 ± 10.8 |
| Diastolic blood pressure (mmHg) | 65.7 ± 9.6 | 68.3 ± 10.5 |
| Oxygen pulse (mL·beat−1) | 2.7 ± 0.7 | 3.6 ± 0.9 |
| VO2 (mL·kg−1.min−1) | 3.1 ± 0.5 | 3.6 ± 0.9 |
| VO2 (L·min−1) | 0.3 ± 0.1 | 0.3 ± 0.1 |
|
| ||
| Heart rate (bpm) | 117.9 ± 17.4 | 104.4 ± 31.5 |
| Oxyhemoglobin saturation (%) | 96.7 ± 2.6 | 96.0 ± 2.9 |
| Systolic blood pressure (mmHg) | 124.9 ± 29.1 | 136.6 ± 26.6 |
| Diastolic blood pressure (mmHg) | 65.7 ± 9.6 | 68.3 ± 10.5 |
| Oxygen pulse (mL·beat−1) | 11.6 ± 4.0 | 11.2 ± 3.8 |
| VO2peak (mL·kg−1.min−1) | 14.9 ± 5.3 | 12.5 ± 3.9 |
| VO2peak (L·min−1) | 1.4 ± 0.5 | 1.1 ± 0.3 |
No significant differences between groups.
Exercise responses during steady state and interval training sessions (values are means ± SD).
|
|
|
|
|---|---|---|
| Heart rate (bpm) | 105 ± 8 | 40%: 91 ± 16 |
| 90%: 109 ± 26 | ||
| Average: 100 ± 21 | ||
| Rating of perceived | 4.2 ± 0.6 | 40%: 3.0 ± 1.2 |
| exertion (0–10) | 90%: 5.6 ± 1.4 | |
| Average: 4.3 ± 1.2 | ||
| Work Rate (W) | 54.6 ± 25.3 | 40%: 31.3 ± 11.8 |
| 90%: 70.3 ± 26.5 | ||
| Average: 50.8 ± 19.1 | ||
| METs | 2.8 ± 1.0 | 40%: 1.4 ± 0.4 |
| 90%: 3.2 ± 1.0 | ||
| Average: 2.3 ± 0.7 | ||
| Rate pressure product | 13,802 ± 2,664 | 40%: 10,869 ± 2,317 |
| (mmHg·bpm) | 90%: 14,539 ± 4,713 | |
| Average: 12,704 ± 3,490 | ||
| Total work (J) | 65,486 ± 30,388 | 60,943 ± 22,978 |
Average refers to the mean response across the 20 min interval session involving 10 min of high and low intensity exercise (90 and 40%, respectively). Total work was calculated across the 20 min exercise session for both training groups.
Significant (p < 0.05) difference between interval training intensities (i.e., 90 > 40%). No significant difference between training groups.
Figure 2Interleukin-6 (IL-6) as a function of time. Means ± SD. *Main effect for time observed immediately post-exercise (p < 0.05). Circle = Steady State; Square = Interval. Error Bars = ± SEM.
Figure 3Interleukin-8 (IL-8) as a function of time. Means ± SD. Circle = Steady State; Square = Interval. Error Bars = ± SEM.
Figure 4Interleukin-10 (IL-10) as a function of time. Means ± SD. Circle = Steady State; Square = Interval. Error Bars = ± SEM.
Figure 5Tumor Necrosis Factor-alpha (TNF-α) as a function of time. Means ± SD. Circle = Steady State; Square = Interval. Error Bars = ± SEM.
Figure 6High sensitivity C-Reactive Protein as a function of time. Means ± SD. Circle = Steady State; Square = Interval. Error Bars = ± SEM.
Baseline relationship between clinical indicators.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
| Ejection Fraction | 1.00 | 0.01 | −0.05 | −0.11 | 0.18 | −0.08 |
| Oxygen Consumption | 0.01 | 1.00 | 0.23 | 0.23 | 0.04 | 0.37 |
| Height | −0.05 | 0.23 | 1.00 | 0.57 | 0.45 | 0.27 |
| Weight | −0.11 | 0.23 | 0.57 | 1.00 | −0.29 | −0.30 |
| NT ProBNP | 0.18 | 0.04 | 0.45 | −0.29 | 1.00 | 0.44 |
| Age | −0.08 | 0.37 | 0.27 | −0.30 | 0.44 | 1.00 |
Marked correlations are significant at p < 0.05. The heat map correlation is designed such that a correlation of −1 is represented with red, a correlation of 0 (mid-point) is represented with yellow, and a correlation of +1 is represented with a color of dark green.
The baseline relationship between various inflammatory biomarkers.
|
|
|
|
|
| |
|---|---|---|---|---|---|
| CRP | 1.00 | 0.65 | 0.81 | 0.43 | 0.44 |
| IL-6 | 0.65 | 1.00 | 0.63 | 0.27 | 0.41 |
| IL-8 | 0.81 | 0.63 | 1.00 | 0.49 | 0.41 |
| IL-10 | 0.43 | 0.27 | 0.49 | 1.00 | 0.36 |
| TNF-α | 0.44 | 0.41 | 0.41 | 0.36 | 1.00 |
NT ProBNP, N-terminal pro b-type natriuretic; CRP, high sensitivity C-Reactive protein; IL-6, Interleukin 6; IL-8, Interleukin 8; IL-10 Interleukin 10; TNF-α, Tumor Necrosis Factor alpha.
Marked correlations are significant at p < 0.05. The heat map correlation is designed such that a correlation of −1 is represented with red, a correlation of 0 (mid-point) is represented with yellow, and a correlation of +1 is represented with a color of dark green.